Literature DB >> 9674003

A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells.

S M el-Harazi1, R S Ruiz, R M Feldman, G Villanueva, A Z Chuang.   

Abstract

BACKGROUND AND
OBJECTIVE: To compare the efficacy of ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing flare and cells following cataract surgery. PATIENTS AND METHODS: Fifty-eight patients undergoing phacoemulsification with posterior chamber intraocular lens implantation were randomly selected to receive either ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, or prednisolone acetate 1% following surgery. The treatment regimen was 1 drop 4 times a day for 1 week, then twice a day for the next 3 weeks. Flare, cells, and intraocular pressures (IOPs) were measured preoperatively and on postoperative days 1, 7, and 28.
RESULTS: No statistically significant differences in either actual flare or cell counts or in change in flare or cell counts from baseline were detected among the three groups. No statistically significant differences in IOP or in change of IOP from preoperative measurements were detected. No medication-related complications were noted at any time.
CONCLUSION: Ketorolac tromethamine 0.5% and diclofenac sodium 0.1% may be as effective and as safe as prednisolone acetate 1% in controlling inflammation following cataract extraction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674003

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers        ISSN: 1082-3069


  15 in total

Review 1.  Laser flare and cell photometry to measure inflammation after cataract surgery: a tool to predict the risk of cystoid macular edema.

Authors:  Michele De Maria; Marco Coassin; Danilo Iannetta; Luigi Fontana
Journal:  Int Ophthalmol       Date:  2021-03-21       Impact factor: 2.031

2.  Comparison of Ketorolac Tromethamine and Prednisolone Acetate in Preventing Surgically Induced Miosis during Cataract Surgery.

Authors:  Yusuf M Suleiman; Najwa F Krdoghli; Aksam J Ahmad
Journal:  Sultan Qaboos Univ Med J       Date:  2010-04-17

3.  Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study.

Authors:  Christoph Hirneiss; Aljoscha S Neubauer; Anselm Kampik; Carl-Ludwig Schönfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

4.  Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac.

Authors:  Guadalupe Cervantes-Coste; Yuriana G Sánchez-Castro; Mónica Orozco-Carroll; Erick Mendoza-Schuster; Cecilio Velasco-Barona
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 6.  Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.

Authors:  Viral V Juthani; Elizabeth Clearfield; Roy S Chuck
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

Review 7.  The role of NSAIDs in the management of postoperative ophthalmic inflammation.

Authors:  Joseph Colin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

9.  Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery.

Authors:  Rahul Reddy; Stephen Jae Kim
Journal:  Clin Ophthalmol       Date:  2011-06-03

10.  Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients.

Authors:  Jiro Numaga
Journal:  J Ophthalmic Inflamm Infect       Date:  2011-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.